indolactam v has been researched along with Breast Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Acs, P; Ahmad, S; Blumberg, PM; Bogi, K; Glazer, RI; Kozikowski, AP; Lewin, NE; Ma, D; Modarres, S; Wang, S; Yao, J | 1 |
Basu, A | 1 |
2 other study(ies) available for indolactam v and Breast Neoplasms
Article | Year |
---|---|
Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivit
Topics: Antineoplastic Agents; Binding Sites; Binding, Competitive; Breast Neoplasms; Cell Division; Crystallography, X-Ray; Enzyme Inhibitors; Female; Humans; Hydrogen Bonding; Indoles; Isoenzymes; Lactams; Lyngbya Toxins; Models, Molecular; Molecular Conformation; Molecular Structure; Mutagenesis, Site-Directed; Protein Kinase C; Tumor Cells, Cultured | 1997 |
The involvement of novel protein kinase C isozymes in influencing sensitivity of breast cancer MCF-7 cells to tumor necrosis factor-alpha.
Topics: Antineoplastic Agents; Breast Neoplasms; Bryostatins; Carcinogens; Enzyme Activation; Enzyme Inhibitors; Humans; Indoles; Isoenzymes; Lactams; Lactones; Macrolides; Maleimides; Phorbol 12,13-Dibutyrate; Protein Kinase C; Receptors, Tumor Necrosis Factor; Sensitivity and Specificity; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1998 |